Camiren XL, tablets 4 mg, 30 pcs.

Doxazosin is a selective competitive blocker of postsynaptic alpha1-adrenoreceptors. By reducing vascular muscle tone doxazosin decreases total peripheral vascular resistance, which leads to a decrease in blood pressure (BP). After a single dose of the drug, the maximum hypotensive effect is observed within 2 to b hours, and in general, the hypotensive effect lasts for 24 hours. During doxazosin treatment in patients with arterial hypertension there is no difference in BP values in standing and lying position.

Effective in arterial hypertension, including that accompanied by metabolic disorders (obesity, decreased glucose tolerance).

Limits the risk of coronary heart disease.

The use of the drug in persons with normal blood pressure (BP) is not accompanied by a decrease in BP. During long-term use of doxazosin in patients no changes in tolerance to the therapeutic antihypertensive effect are observed.
During doxazosin treatment a decrease in plasma concentration of triglycerides and total cholesterol is observed. At the same time there is a certain (by 4 – 13%) increase of HDL/total cholesterol ratio.

On long-term treatment with doxazosin regression of left ventricular hypertrophy, suppression of platelet aggregation and increase of active plasminogen in tissues is observed.

Due to the fact that doxazosin blocks alpha1-adrenoreceptors located in stroma and capsule of prostate and in bladder neck, there is decrease of resistance and pressure in urethra, decrease of internal sphincter resistance. Therefore, administration of doxazosin to the patients with symptoms of benign prostatic hyperplasia leads to significant improvement of urodynamic indexes and reduction of manifestations of the disease symptoms. It has the effect in 66-71 % of the patients, the beginning of the effect – after 1-2 weeks of the treatment, maximum – after 14 weeks, the effect is preserved for a long time. Compared with the drug in tablets and the drug in the dosage form of tablets with modified release, the latter improves the ratio of efficacy and safety. Doxazosin is a selective competitive blocker of postsynaptic alpha1-adrenoreceptors. By reducing vascular muscle tone, doxazosin reduces total peripheral vascular resistance, which leads to a decrease in blood pressure (BP). After a single dose of the drug, the maximum hypotensive effect is observed within 2 to b hours, and in general, the hypotensive effect lasts for 24 hours. During doxazosin treatment in patients with arterial hypertension there is no difference in BP values in standing and lying position.
Effective in arterial hypertension, including that accompanied by metabolic disorders (obesity, decreased glucose tolerance).

Limits the risk of coronary heart disease.

The use of the drug in persons with normal blood pressure (BP) is not accompanied by a decrease in BP. During long-term use of doxazosin in patients no changes in tolerance to the therapeutic antihypertensive effect are observed.
During doxazosin treatment a decrease in plasma concentration of triglycerides and total cholesterol is observed. At the same time there is a certain (by 4 – 13%) increase of HDL/total cholesterol ratio.

On long-term treatment with doxazosin regression of left ventricular hypertrophy, suppression of platelet aggregation and increase of active plasminogen in tissues is observed.

Due to the fact that doxazosin blocks alpha1-adrenoreceptors located in stroma and capsule of prostate and in bladder neck, there is decrease of resistance and pressure in urethra, decrease of internal sphincter resistance. Therefore, administration of doxazosin to the patients with symptoms of benign prostatic hyperplasia leads to significant improvement of urodynamic indexes and reduction of manifestations of the disease symptoms. It has the effect in 66-71 % of the patients, the beginning of the effect – after 1-2 weeks of the treatment, maximum – after 14 weeks, the effect is preserved for a long time. Compared to the drug in tablets and the drug in the dosage form of modified-release tablets, the latter improves the ratio of efficacy to safety.

Indications

The drug is recommended for the treatment of mild to moderate arterial hypertension (in combination with other antihypertensive agents – thiazide diuretics, beta-adrenoblockers, slow calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors) and for symptomatic treatment of benign prostatic hyperplasia.

Active ingredient

Composition

1 modified-release tablet contains the active ingredient doxazosin mesylate 4.85 mg (corresponding to 4 mg of doxazosin).

Auxiliary substances:

hypromellose,

calcium hydrophosphate anhydrous,

How to take, the dosage

Orally, once a day (morning or evening) regardless of meals, without chewing and with plenty of water.
The drug dose should be adjusted depending on the effectiveness of the drug or possible side effects in individual patients. Patients with hepatic impairment require smaller doses due to slower metabolism of the drug.

If a patient forgets to take the drug at the usual time, he should take the appropriate dose of the drug as soon as possible. If it is time for the next dose, only this dose should be taken (not doubling the dose of the medication). It is important to take the medication regularly. If the patient has not taken the medication for several days, the new course of therapy should be started with the lowest dose.

Hypertension: The usual dose of Camiren XL is 1 tablet (4 mg) per day. Its effect can be observed on the first day, therapeutic effect comes 4 weeks after the start of treatment. After 4 weeks, in case of good tolerance of the drug and if the doctor considers the effect to be insufficient, higher doses may be prescribed. Maximum recommended daily dose of Camiren XL is 2 tablets (8 mg) at a time.

If the therapeutic effect is insufficient, patients may receive other antihypertensive agents at the same time: beta-adrenoblockers, diuretics, slow calcium channel blockers and ACE inhibitors.

After achieving a sustained therapeutic effect, the dose is usually slightly reduced (the average therapeutic dose in maintenance therapy is usually 2-4 mg per day), you can switch to taking CAMIREN, tablets of 2 or 4 mg.
Benign prostatic hyperplasia in patients with normal BP: The usual dose is 1 tablet (4 mg) of CAMIREN CHL per day. The patient should take the first dose in the evening before going to bed. Depending on the effect of the drug, the dose can be gradually increased at intervals of 1-2 weeks to 8 mg once a day. As a rule, the average daily dose is 2 mg to 4 mg, you can switch to taking CAMIREN, tablets of 2 or 4 mg The maximum daily dose is 8 mg.

Benign prostatic hyperplasia in patients with arterial hypertension: doses of the drug are the same as for arterial hypertension without benign prostatic hyperplasia (see doses for arterial hypertension).

The drug is used for a long time. The duration of treatment is determined by the attending physician.

Interaction

Doxazosin enhances the hypotensive effect of antihypertensive agents.

No adverse interaction has been noted with concomitant use of doxazosin and thiazide diuretics, furosemide, beta-adrenoblockers, slow calcium channel blockers, ACE inhibitors, antibiotics, oral hypoglycemic agents, indirect anticoagulants and urocautery agents.

Concomitant use with inducers of microsomal oxidation in the liver may increase the effectiveness of doxazosin, with inhibitors – decrease the effectiveness.

NSAIDs (especially indomethacin), sympathomimetic agents may decrease the hypotensive effect of doxazosin. Since estrogens may cause fluid retention in the body, simultaneous use may also decrease the hypotensive effect of doxazosin.

By eliminating the alpha-adrenergic stimulating effects of epinephrine, doxazosin may cause tachycardia and arterial hypotension.

Special Instructions

Special caution should be exercised when prescribing this drug to patients with impaired liver function, especially in cases when concomitant use of drugs that may adversely affect liver function. In case of liver function abnormalities the drug should be immediately discontinued.

In order to prevent orthostatic reactions, patients should avoid sudden and abrupt changes of body position (transition from “lying” to “standing” position).

The intake of alcohol can increase unwanted reactions.

The safety and effectiveness of doxazosin in children has not been established, so it is not recommended to prescribe the drug in children.

The effect of “first” administration of the drug is particularly pronounced with prior diuretic therapy and a sodium-restricted diet.

Before starting therapy, prostate cancer must be excluded.

Due to the fact that doxazosin is able to cause orthostatic reactions at the beginning of treatment or during dose escalation, patients should refrain from all potentially dangerous activities, particularly from driving motor vehicles and other vehicles and mechanisms.

Contraindications

Camiren XL should not be administered to patients with hypersensitivity to doxazosin and other quinazoline derivatives (prazosin, terazosin) or other components of the drug, under the age of 18 years (effectiveness and safety are not established).

With caution use in patients with aortic or mitral stenosis, patients with impaired hepatic and/or renal function, orthostatic hypotension.

Side effects

Arterial hypertension

In clinical studies, orthostatic hypotension, which in rare cases may lead to fainting, has been observed most frequently, especially at the beginning of treatment.

General reactions: asthenia, fatigue, malaise.

Cardiovascular system: edema, fainting.

By eliminating the alpha-adrenergic stimulating effects of epinephrine, may lead to tachycardia and arterial hypotension.

Overdose

Symptoms: marked decrease in BP, sometimes accompanied by fainting.

Treatment: the patient should be transferred immediately to a horizontal position on the back with a low headboard. Administer symptomatic therapy. Dialysis is ineffective.

Pregnancy use

Pregnant women may prescribe the drug only for vital signs when the benefit to the mother outweighs the potential risk to the fetus/infant.

The safety of the drug in breastfed children has not been established; therefore, breastfeeding mothers are advised to stop breastfeeding during treatment with doxazosin.

Similarities